Last updated 44 hours ago

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

276 patients around the world

Available in Chile

AbbVie

3Research sites

276Patients around the world

This study is for people with

Crohn's disease

From 18 Years

All Gender

: Biopsy-confirmed diagnosis of CD for at least 3 months prior to Baseline.
Participant meets the following disease activity criteria.
Moderate to severe CD as assessed by CDAI.
Endoscopic evidence of mucosal inflammation as documented by a SES-CD.
Participant has demonstrated intolerance, loss of response or inadequate response to conventional or advanced therapies for CD.

: Participants with a current diagnosis of ulcerative colitis or indeterminate colitis.
Participants with unstable doses of concomitant Crohn's disease therapy.
Participants with prior exposure to p19 inhibitors.
Participants with complications of Crohn's disease.
Participants having an ostomy or ileoanal pouch.

Clínica Dermacross S.A. - Vitacura - Santiago

Recruiting

Av. Manquehue Norte 2051 C, Vitacura, Metropolitana, 7640881

Clínica Universidad de los Andes

Recruiting

Av Plaza 2501, Las Condes, Región Metropolitana, Santiago

Espacio EME

Recruiting

Av. Ricardo Lyon 2911, Ñuñoa Región Metropolitana

StudyRisa CD SubQ

SponsorAbbVie

Conditions

Crohn's disease

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06063967